Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
- 5 August 2025
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (2) , 350-361
Abstract
Bispecific T‐cell engagers (Bi‐TCEs) have demonstrated clinical efficacy and safety, with 7 approved for hematological cancers and 2 approved for solid tumors by the US Food and Drug Administration (FDA) as of May 2025. Its intricate mechanism of action through the formation of a trimer involving Bi‐TCE, T cell, and tumor cell presents challenges to clinical development requiring special strategies for multiple disciplines. This review summarizes key clinical pharmacology characterizations of these 9 FDA‐approved Bi‐TCEs to understand the current practice and to identify potential knowledge gaps. The topics covered include dosing strategies, general clinical pharmacology evaluations, and cytokine‐related drug–drug interaction (DDI) assessment. The dosing strategy part discusses the criteria for step‐up dose and full treatment dose selection, the potential for further optimization of dose regimen in later cycles, and the analyses supporting the restarting strategy after dosage delay. The section on general clinical pharmacology evaluations summarizes pharmacokinetic (PK) property and its impact on dosing strategy, PK in specific populations (e.g., organ impairment, pediatrics), pharmacodynamics property, and immunogenicity information. The cytokine‐related DDI part discusses cytokine profiles, risk mitigation strategy, and physiologically based PK (PBPK) models and their limitations. Finally, future perspectives are provided regarding efficient dose selection, PBPK modeling application, and Bi‐TCEs for solid tumors and non‐oncology indications.Keywords
This publication has 20 references indexed in Scilit:
- Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic ModelTargeted Oncology, 2024
- Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in OncologyClinical Pharmacology & Therapeutics, 2024
- Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamabCPT: Pharmacometrics & Systems Pharmacology, 2024
- Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modelingCPT: Pharmacometrics & Systems Pharmacology, 2023
- T-cell-engaging bispecific antibodies in cancerThe Lancet, 2023
- Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID‐19 PatientsClinical Pharmacology & Therapeutics, 2021
- Overcoming the challenges associated with CD3+ T-cell redirection in cancerBritish Journal of Cancer, 2021
- Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva CocktailClinical Pharmacology & Therapeutics, 2020
- Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its ImplicationsClinical Pharmacokinetics, 2016
- Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial DesignClinical Pharmacology & Therapeutics, 2010